Associated Papers
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Lunenburg CATC et al.
European Journal of Human Genetics : Ejhg, 2020
Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs.
Sharma V et al.
Cancer Chemotherapy and Pharmacology, 2019
Association and prediction of severe 5-fluorouracil toxicity with dihydropyrimidine dehydrogenase gene polymorphisms: A meta-analysis.
Leung HW et al.
Biomedical Reports, 2015
Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients.
Del Re M et al.
The Epma Journal, 2015
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
Rosmarin D et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2014
Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?
Ciccolini J et al.
Clinical Colorectal Cancer, 2010
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
Del Re M et al.
The Epma Journal, 2010
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients.
He YF et al.
Journal of Clinical Pharmacy and Therapeutics, 2008
SSCP screening of the dihydropyrimidine dehydrogenase gene polymorphisms of the Japanese population using a semi-automated electrophoresis unit.
Okamoto Y et al.
Biochemical Genetics, 2007
[The association between DPYD gene polymorphism and chemotherapeutic toxicity of 5-FU in gastric carcinoma and colonic carcinoma].
Zhang H et al.
Zhonghua Nei Ke Za Zhi, 2007
Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.
Maekawa K et al.
Journal of Human Genetics, 2007
DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.
Zhang H et al.
Medical Oncology (northwood, London, England), 2007
Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
Mercier C et al.
Clinical Colorectal Cancer, 2006
Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant.
Lazar A et al.
Onkologie, 2004
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Lee A et al.
Clinical Advances in Hematology & Oncology : H&o, 2004
Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.
Hsiao HH et al.
Cancer Chemotherapy and Pharmacology, 2004
Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
Ezzeldin H et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2003
5-fluorouracil and dihydropyrimidine dehydrogenase.
Kubota T
International Journal of Clinical Oncology, 2003
Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil.
Yamaguchi K et al.
Japanese Journal of Cancer Research : Gann, 2001
Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.
Johnson MR et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 1999